China's Largest Eye Hospital Chain Plans HK Listing in Move That Could Boost Healthcare Sector Momentum

China's leading eye hospital chain, operating over 120 facilities across the country, is in advanced discussions to list on the Hong Kong Stock Exchange, according to multiple industry sources. The company, which remains unnamed in public filings but is known to serve more than 3 million patients annually, aims to raise up to HK$2.3 billion (approximately $300 million) through the IPO. This move would represent one of the largest healthcare-related listings in Hong Kong this year and signal growing investor confidence in China's specialized medical services sector. The anticipated listing comes amid broader market trends favoring healthcare infrastructure and outpatient care providers. With China’s aging population and rising prevalence of vision disorders, demand for high-quality ophthalmic services continues to expand. The hospital chain has reported consistent revenue growth of 18% year-over-year over the past three fiscal years, underpinned by expanding private partnerships and digital health integrations. The IPO could have ripple effects on related equities, particularly in the healthcare sector. ETFs tracking Chinese healthcare stocks, such as the iShares China Large-Cap ETF (XLV), may see increased inflows as institutional investors seek exposure to high-growth medical service providers. The stock ticker 00700.HK, currently used by a major Chinese healthcare conglomerate, may also experience heightened market attention if the new listing enters trading under a similar symbol or is grouped into the same sector index. The timing of the listing coincides with enhanced regulatory clarity from Hong Kong’s Securities and Futures Commission on healthcare IPOs, easing approval pathways for specialized medical operators. The company is expected to file its red herring prospectus by mid-April, with a potential launch in June 2026.